These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 38756644)

  • 1. Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study.
    Li RR; Zhou HJ; Zeng DY; Jiang SF; Liu W; Frühling P; Liu ZY
    J Gastrointest Oncol; 2024 Apr; 15(2):612-629. PubMed ID: 38756644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
    Ciardiello D; Martinelli E; Troiani T; Mauri G; Rossini D; Martini G; Napolitano S; Famiglietti V; Del Tufo S; Masi G; Santini D; Avallone A; Pietrantonio F; Lonardi S; Di Maio M; Zampino MG; Fazio N; Bardelli A; Siena S; Cremolini C; Sartore-Bianchi A; Ciardiello F
    JAMA Netw Open; 2024 Apr; 7(4):e245635. PubMed ID: 38592721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
    Okunaka M; Kawazoe A; Nakamura H; Kotani D; Mishima S; Kuboki Y; Nakamura Y; Shitara K
    Gastric Cancer; 2023 Nov; 26(6):1030-1039. PubMed ID: 37665515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis.
    Aquino de Moraes FC; Dantas Leite Pessôa FD; Duarte de Castro Ribeiro CH; Rodrigues Fernandes M; Rodríguez Burbano RM; Carneiro Dos Santos NP
    BMC Cancer; 2024 Jun; 24(1):674. PubMed ID: 38825703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer.
    Prager GW; Taieb J; Fakih M; Ciardiello F; Cutsem EV; Élez E; Wyrwicz L; Stroyakovskiy D; Liposits G; Bondarenko I; Modest DP; Amellal N; Tabernero J;
    Future Oncol; 2024 Jul; ():1-10. PubMed ID: 38953855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.
    Zhang J; Yang W; Liu J; Wang N; Ren Z; Yang T; Xie G; Wu G; Sun Y
    Invest New Drugs; 2024 Jul; ():. PubMed ID: 38990451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a retrospective cohort study.
    Yan H; Liu J; Zhang Y; Chen S; Xu J; Gao D; Li H; Fang X; Wang Y; Wang H; Wang H
    J Gastrointest Oncol; 2024 Jun; 15(3):987-1001. PubMed ID: 38989408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC.
    Bando H; Kotani D; Satake H; Hamaguchi T; Shiozawa M; Kotaka M; Masuishi T; Yasui H; Kagawa Y; Komatsu Y; Oki E; Yamamoto Y; Kawakami H; Misumi T; Taniguchi H; Yamazaki K; Muro K; Yoshino T; Kato T; Tsuji A
    Med; 2024 Jun; ():. PubMed ID: 38901425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer.
    An TQ; Qiu H; Zhou QB; Zong H; Hu S; Lian YG; Zhao RH
    World J Gastrointest Oncol; 2024 Jun; 16(6):2449-2462. PubMed ID: 38994132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US.
    Paly VF; Dasari A; Hubbard J; Bekaii-Saab T; Padukkavidana T; Hernandez L
    J Comp Eff Res; 2024 Jul; ():e240084. PubMed ID: 38976346
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study).
    Calegari MA; Zurlo IV; Dell'Aquila E; Basso M; Orlandi A; Bensi M; Camarda F; Anghelone A; Pozzo C; Sperduti I; Salvatore L; Santini D; Corsi DC; Bria E; Tortora G
    Clin Colorectal Cancer; 2024 Jun; ():. PubMed ID: 38969549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of FOLFOXIRI Plus Bevacizumab and Subsequent Therapies in Metastatic Colorectal Cancer: An Age-Stratified Analysis.
    Vassilev ZP; Fan X; Xu J; Ostojic H; Barzi A
    Clin Colorectal Cancer; 2024 May; ():. PubMed ID: 38853099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
    Kawazoe A; Xu RH; García-Alfonso P; Passhak M; Teng HW; Shergill A; Gumus M; Qvortrup C; Stintzing S; Towns K; Kim TW; Shiu KK; Cundom J; Ananda S; Lebedinets A; Fu R; Jain R; Adelberg D; Heinemann V; Yoshino T; Elez E;
    J Clin Oncol; 2024 Jun; ():JCO2302736. PubMed ID: 38833658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The salvage lenvatinib-based regimen provides survival benefit in patients with refractory metastatic colorectal cancer.
    Kao YC; Yang MY; Chen WS; Jiang JK; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Huang SC; Cheng HH; Lin YZ; Yang YW; Teng HW
    Am J Cancer Res; 2024; 14(5):2187-2201. PubMed ID: 38859851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves.
    Obeng-Kusi M; Martin JR; Roe D; Erstad BL; Abraham I
    Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; ():. PubMed ID: 38845342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effect of dose-dense paclitaxel plus carboplatin with or without bevacizumab for Japanese patients with epithelial ovarian cancer.
    Kochi Y; Hosoya S; Yanaihara N; Nagata C; Honda R; Shimazaki M; Yokosu K; Kuroda T; Saito M; Tanabe H; Yamada K; Takano H; Okamoto A
    Int J Clin Oncol; 2024 Jun; ():. PubMed ID: 38865025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
    Cohen R; Raeisi M; Chibaudel B; Shi Q; Yoshino T; Zalcberg JR; Adams R; Cremolini C; Van Cutsem E; Heinemann V; Tabernero J; Punt CJA; Arnold D; Hurwitz HI; Douillard JY; Venook AP; Saltz LB; Maughan TS; Kabbinavar F; Bokemeyer C; Grothey A; Mayer RJ; Kaplan R; Tebbutt NC; Randolph Hecht J; Giantonio BJ; Díaz-Rubio E; Sobrero AF; Peeters M; Koopman M; Goldberg RM; Andre T; de Gramont A
    Eur J Cancer; 2024 Jun; 207():114160. PubMed ID: 38896997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer.
    Zhong J; Liu Y; Fu Q; Huang D; Gong W; Zou J
    Cancer Manag Res; 2024; 16():593-602. PubMed ID: 38855331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of potentiation of pembrolizumab with binimetinib and bevacizumab in refractory microsatellite stable colorectal cancer.
    Lentz RW; Friedrich TJ; Blatchford PJ; Jordan KR; Pitts TM; Robinson HR; Davis SL; Kim SS; Leal AD; Lee MR; Waring MRN; Martin AC; Dominguez ATA; Bagby SM; Hartman SJ; Eckhardt SG; Messersmith WA; Lieu CH
    Clin Cancer Res; 2024 Jun; ():. PubMed ID: 38869830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial.
    Martinelli E; Ciardiello D; Martini G; Napolitano S; Del Tufo S; D'Ambrosio L; De Chiara M; Famiglietti V; Nacca V; Cardone C; Avallone A; Cremolini C; Pietrantonio F; Maiello E; Granata V; Troiani T; Cappabianca S; Ciardiello F; Nardone V; Reginelli A
    Clin Drug Investig; 2024 Jun; ():. PubMed ID: 38886336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.